Kymera Therapeutics, Inc. (KYMR) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics using targeted protein degradation (TPD). The company has no approved products and generates revenue solely through collaboration agreements. As of September 30, 2025, the company had 71,949,027 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Collaboration Revenue | $2,764 | $3,741 | $36,341 | $39,678 |
| Net Loss | $(82,175) | $(62,487) | $(224,370) | $(153,106) |
| Loss Per Share (Basic/Diluted) | $(0.94) | $(0.82) | $(2.71) | $(2.09) |
| Operating Expenses | $95,285 | $75,865 | $287,844 | $220,558 |
| Cash & Cash Equivalents | $112,949 | $110,718 | Total Liquidity (Cash + Marketable Securities): $978.7M | |
| Marketable Securities | $865,787 | $730,647 | ||
| Accumulated Deficit | $(978,980) | $(683,858) | As of Sept 30, 2025 |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by 26% in Q3 2025 compared to Q3 2024 ($2.8M vs $3.7M). This shift reflects the transition from the Sanofi collaboration (which drove Q3 2024 revenue) to the new Gilead agreement (which drove Q3 2025 revenue).
- Increased Operating Loss: Net loss widened by 32% in Q3 2025 ($82.2M) compared to Q3 2024 ($62.5M). The nine-month net loss increased by 47% ($224.4M vs $153.1M).
- R&D Expense Surge: Research and development expenses increased by 23% in Q3 2025 ($74.1M vs $60.4M), primarily driven by an $8.3M increase in costs related to the STAT6 program (KT-621) and increased personnel costs.
- Impairment Charge: The company recorded a $3.9 million impairment charge in Q3 2025 related to long-lived assets (specifically the 2019 Lease facility) due to declining market conditions for office/lab space. No such charge was recorded in Q3 2024.
- Capital Raise: In June 2025, the company completed a follow-on public offering, raising approximately $288.4 million in gross proceeds.
Guidance, Outlook, and Management Commentary
- Liquidity Runway: Management states that as of September 30, 2025, the company holds $978.7 million in cash, cash equivalents, and marketable securities. This is projected to fund operations into the second half of 2028, extending beyond multiple clinical inflection points.
- Pipeline Updates:
- STAT6 (KT-621): Completed dosing in the BroADen Phase 1b trial and initiated the BroADen2 Phase 2b clinical trial for Atopic Dermatitis.
- IRF5 (KT-579): Completed IND-enabling studies in May 2025.
- IRAK4 (KT-485): Sanofi exercised its full participation election to advance this next-generation degrader into clinical testing in 2026, discontinuing the previous candidate (KT-474).
- CDK2: Entered a new strategic collaboration with Gilead in June 2025 to develop molecular glue degraders, receiving a $40.0 million upfront payment.
- TYK2 (KT-295): Management announced a strategic decision in May 2025 not to advance this program into clinical development to conserve resources for other immunology programs.
- Risks: The filing highlights significant risks regarding the company's unproven TPD technology, the uncertainty of clinical trial results, and the need for substantial additional funding in the future. The company also notes potential impacts from a U.S. federal government shutdown affecting FDA review timelines.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $978.7M liquidity position against the accelerating R&D spend (up $64.3M in the first nine months of 2025).
- STAT6 Clinical Data: Monitor upcoming data readouts from the BroADen2 Phase 2b trial for KT-621, as this is the most advanced asset.
- Gilead Option Exercise: Track whether Gilead exercises its option to license the CDK2 program, which would trigger a $45.0 million payment.
- Sanofi Milestones: Confirm the timeline for Sanofi's advancement of KT-485 into clinical testing in 2026 and associated milestone payments.
- Lease Impairment: Assess if further impairment charges are likely regarding the subleasing of the 2019 Watertown facility.